Tempest Therapeutics
TPST
33 hedge funds and large institutions have $5.66M invested in Tempest Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 7 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
43% more capital invested
Capital invested by funds: $3.94M → $5.66M (+$1.71M)
18% more funds holding
Funds holding: 28 → 33 (+5)
0.33% more ownership
Funds ownership: 0.86% → 1.2% (+0.33%)
66% less call options, than puts
Call options by funds: $45K | Put options by funds: $131K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$3.48M |
| 2 |
Jane Street
New York
|
+$490K |
| 3 |
Millennium Management
New York
|
+$188K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$186K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$763K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$133K |
| 3 |
Morgan Stanley
New York
|
-$69.7K |
| 4 |
FW
FullCircle Wealth
Dallas,
Texas
|
-$68.2K |
| 5 |
Empower Advisory Group
Greenwood Village,
Colorado
|
-$49K |
TPST Hedge Fund Activity: Q4 2024 in Review
33 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q4 2024, worth a combined $5.66M — up 43% from $3.94M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new TPST positions and 7 closed out — a net gain of 5 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $3.48M. The largest seller was Altium Capital Management, exiting entirely with an estimated $763K sold.
- 33 institutional investors held Tempest Therapeutics (TPST) as of Q4 2024, up from 28 in Q3 2024.
- Funds reported $5.66M of Tempest Therapeutics stock for Q4 2024, up 43% quarter-over-quarter.
- 12 funds opened new Tempest Therapeutics positions in Q4 2024 and 7 closed out, a net change of +5 holders.
- The largest Tempest Therapeutics buyer in Q4 2024 was Versant Venture Management, an estimated $3.48M added.
- The largest Tempest Therapeutics seller in Q4 2024 was Altium Capital Management, an estimated $763K sold.
Based on aggregated 13F filings for Q4 2024.